ÂÜÀòÂÒÂ×

James Parsons is an experienced financial executive with a strong background in the life sciences and biotechnology sectors. Currently serving as the Director and Chair of the Audit Committee at Sernova Corporation since April 2012 and DiaMedica Therapeutics Inc. since October 2015, James has been integral in overseeing financial operations and governance. As President of Empar Management since April 2003, James provides CFO consulting services, including financing, licensing, and investor relations. Previous roles include Chief Financial Officer positions at Trillium Therapeutics Inc., the Centre for Commercialization of Regenerative Medicine, and ProMIS Neurosciences, among others. James holds a Master of Accounting degree in Accounting and Finance from the University of Waterloo.